6,8-二氟苯并二氢吡喃-4-酮 | 259655-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 6,8-二氟苯并二氢吡喃-4-酮
• 英文名称: 6,8-difluorochroman-4-one
• 英文别名: 6,8-difluoro-2,3-dihydrochromen-4-one
• CAS: 259655-01-1
• 化学式: C₉H₆F₂O₂
• mdl: MFCD01764784
• 分子量: 184.142
• InChiKey: IYQNYCVNEQXHGU-UHFFFAOYSA-N

物化性质

• 沸点：
  282.9±40.0 °C(Predicted)
• 密度：
  1.392±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302,H315,H320,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  6,8-二氟苯并二氢吡喃-4-酮 、 甲基溴化镁 在 氯化铵 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 heptanes 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以to yield 6,8-difluoro-4-methylchroman-4-ol in 84% yield的产率得到6,8-difluoro-4-methylchroman-4-ol
  参考文献：
  名称：

  NOVEL KINASE INHIBITORS

  摘要：

  本发明提供了I式化合物及其相关化合物，以及包括这些化合物的药物组合物。本发明还提供了使用这些化合物和组合物治疗与不良Pim激酶活性水平相关的疾病的方法，包括癌症和自身免疫性疾病。

  公开号：

  US20120225062A1
• 作为产物：
  描述：

  3-(2,4-二氟苯氧基)丙酸 在 五氯化磷 、 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 6,8-二氟苯并二氢吡喃-4-酮
  参考文献：
  名称：

  Synthesis, determination of absolute configuration, and biological evaluation of spiro-fused thiadiazoline inhibitors of kinesin spindle protein (KSP)

  摘要：

  A facile and highly convergent synthesis of biologically active spiro-fused thiadiazoline KSP inhibitors is reported. The highlights of the synthesis include the Michael reaction and cyclization of thiosemicarbazone to 1,3,4-thiadiazoline. This chemistry lends itself to the preparation of (+)-2, a potent and orally bioavailable anti-cancer agent, and to the development of a structure-activity relationship program. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.09.066

文献信息

• EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS
  申请人：Bosmans Jean-Paul R.M.A.

  公开号：US20100280025A1

  公开（公告）日：2010-11-04

  The present invention is related to novel compounds of formula (I) having equilibrative nucleoside transporter ENT1 inhibiting properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the inhibition of ENT1 receptors in animals, in particular humans.
• US8263592B2
  申请人：——

  公开号：US8263592B2

  公开（公告）日：2012-09-11
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2012120428A1

  公开（公告）日：2012-09-13

  The present invention provides compounds of Formula I: (I) and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pirn kinase activity, including cancers and autoimmune disorders.
• NOVEL KINASE INHIBITORS
  申请人：Burger Matthew

  公开号：US20120225062A1

  公开（公告）日：2012-09-06

  The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.

  本发明提供了如下式的化合物： 以及本文进一步描述的相关化合物，以及包含这些化合物的药物组合物。该发明还提供了使用这些化合物和组合物治疗与Pim激酶活性不良水平相关的疾病的方法，包括癌症和自身免疫性疾病。
• Synthesis, determination of absolute configuration, and biological evaluation of spiro-fused thiadiazoline inhibitors of kinesin spindle protein (KSP)
  作者：Angie R. Angeles、Liping Yang、Chaoyang Dai、Andrew Brunskill、Andrea D. Basso、M. Arshad Siddiqui

  DOI：10.1016/j.tetlet.2010.09.066

  日期：2010.12

  A facile and highly convergent synthesis of biologically active spiro-fused thiadiazoline KSP inhibitors is reported. The highlights of the synthesis include the Michael reaction and cyclization of thiosemicarbazone to 1,3,4-thiadiazoline. This chemistry lends itself to the preparation of (+)-2, a potent and orally bioavailable anti-cancer agent, and to the development of a structure-activity relationship program. (C) 2010 Elsevier Ltd. All rights reserved.